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ORIGINAL INVESTIGATION
Managed Problem Solving for Antiretroviral
Therapy Adherence
A Randomized Trial
Robert Gross, MD, MSCE; Scarlett L. Bellamy, ScD; Jennifer Chapman, MPH;
Xiaoyan Han, MS; Jacqueline O’Duor, MSW; Steven C. Palmer, PhD;
Peter S. Houts, PhD; James C. Coyne, PhD; Brian L. Strom, MD, MPH
Background:Adherence to antiretroviral therapy is criti-
cal to successful treatment of human immunodeficiency
virus (HIV). Few interventions have been demonstrated to
improvebothadherenceandvirologicoutcomes.Wesought
to determine whether an intervention derived from prob-
lem solving theory, Managed Problem Solving (MAPS),
would improve antiretroviral outcomes.
Methods:Weconducted a randomized investigator blind
trial of MAPS compared with usual care in HIV-1 in-
fected individuals at 3 HIV clinics in Philadelphia, Penn-
sylvania. Eligible patients had plasma HIV-1 viral loads
greater than 1000 copies/mL andwere initiating or chang-
ing therapy. Managed Problem Solving consists of 4 in-
person and 12 telephone-based meetings with a trained
interventionist, then monthly follow-up calls for a year.
Primary outcome was medication adherence measured
using electronicmonitors, summarized as fraction of doses
taken quarterly over 1 year. Secondary outcome was un-
detectable HIV viral load over 1 year. We assessed 218
for eligibility, with 190 eligible and 180 enrolled, 91 ran-
domized to MAPS and 89 to usual care. Fifty-six partici-
pants were lost to follow-up: 33 in the MAPS group and
23 in usual care group.
Results: In primary intention-to-treat analyses, the odds
of being in a higher adherence category was 1.78 (95%
CI,1.07-2.96) times greater for MAPS than usual care. In
secondary analyses, the odds of an undetectable viral load
was 1.48 (95%CI, 0.94-2.31) times greater forMAPS than
usual care. In as-treated analyses, the effect of MAPS was
stronger for both outcomes. There was neither a differ-
encebyprior treatment statusnor change ineffect over time.
Conclusions: Managed Problem Solving is an effective
antiretroviral adherence intervention over the first year
with a new regimen. It was equally effective at improv-
ing adherence in treatment experienced and naı¨ve pa-
tients and did not lose effect over time. Implementation
of MAPS should be strongly considered where re-
sources are available.
Trial Registration: clinicaltrials.gov Identifier:
NCT00130273
JAMA Intern Med. 2013;173(4):300-306.
Published online January 28, 2013.
doi:10.1001/jamainternmed.2013.2152
A DHERENCE TO PHARMACO-therapy is key to prevent-ing progression of treat-able chronic diseases.Unfortunately, clinically
significantnonadherence is common india-
betes mellitus,1 hypertension,2 hypercho-
lesterolemia,3 and human immunodefi-
ciencyvirus (HIV),4 for example.Adherence
barriers include depression,5 substance
abuse,6 regimen complexity,7 poor social
support,8 and lowhealth literacy,9,10 among
others. Adherence interventions have had
limited effects, which oftenwane over sub-
sequent months.11-13
Patients may have multiple adherence
barriers, and so personalized strategies ad-
dressing multiple barriers hold the great-
est promise for success.WedevelopedMan-
aged Problem Solving (MAPS) to address
barriers to chronic pharmacotherapy ad-
herence. It derives from Problem Solving
Therapy (PST), an effective intervention for
depression.14 Problem Solving Therapy
trains individuals in generalizable problem-
solving skills including identification of
difficulties, generation of solutions, and
evaluation of outcomes.15 It has been
adapted to address copingwith cancer and
schizophrenia, family caregiving, and fam-
ily relationships.16-18 Managed Problem
Solving differs fromPST; the participant is
not trained to become a better generalized
problem solver per se. Rather, the inter-
ventionist and participantwork together to
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solve specific adherence barriers using the Problem Solv-
ing framework. An overlapwith PST is startingwith small,
achievable goals to ensure success and establish credibil-
ity. Notably, MAPS does address some problems that pa-
tients believe are important but are only indirectly re-
lated tomedication adherence. This may reduce stressors
that interfere with adherence and encourage continued
participation.
We assessed whether MAPS resulted in better adher-
ence to therapy for HIV than usual care. We chose anti-
retroviral therapy because the relationship between ad-
herence and outcomewas well described,19-22 as were the
ensuing consequences of disease progression,23 further
HIV transmission,24 and emergence of resistance.25
METHODS
ETHICS STATEMENT
The study was approved by the committee on human subjects
research of the University of Pennsylvania and the Philadel-
phia Veterans Affairs Medical Center. All participants pro-
vided informed consent and were compensated $30 per data
collection visit, but not intervention visits, for a total of $270
if all visits were completed. A data and safety monitoring com-
mittee reviewed severe intervention-related adverse events (eg,
suicidality). There were no early stopping rules.
STUDY SETTING AND PARTICIPANTS
We conducted a randomized investigator-blind trial compar-
ing MAPS with usual care in HIV-1 infected individuals. Re-
cruitment was facilitated by flyers in the clinics andweekly que-
rying of pharmacists and prescribers regarding potential patients
at the 2 HIV clinics in the University of Pennsylvania Health
System and the HIV clinic at the Philadelphia Veterans Admin-
istration Medical Center. Usual care included meeting with a
pharmacist for regimen education and, if desired, provision of
pill organizers.
Inclusion criteria were at least 18 years old, with HIV-1
plasma viral load greater than 1000 copies/mL, and were treat-
ment naı¨ve and initiating a standard regimen, or treatment ex-
perienced and either (1) restarting their most recent suppres-
sive regimen after more than 3 months off or (2) initiating a
new regimen with 3 new antiretrovirals with resistance pro-
files different from their initial regimen or fully susceptible on
an HIV resistance assay. After study initiation, we expanded
criteria to include regimens with at least 2 fully active and 1
partially active drug based on a resistance assay. Treatment re-
sponses for this subpopulation were expected to be suffi-
ciently similar to those for fully active regimens to allow for
valid conclusions regarding the effect of the intervention on
virologic outcome.26 Exclusion criteria were inability to con-
sent and residence in a setting with automatic medication
delivery.
Permuted block randomization with 1:1 allocation was per-
formed in random block sizes of 6 to 9 individuals. The bio-
statistician generated a randomization list by computer and
placed assignments into sealed security envelopes numbered
sequentially and maintained in a locked drawer by the study
coordinator. At enrollment, the study coordinator selected the
next envelope, which was opened only after consent. The in-
vestigators were blinded by prohibiting their access to the data
and contact with participants.
INTERVENTIONISTS AND INTERVENTION
Interventionistswere required to have a college degree and some
prior experienceworkingwith a patient population.We trained
3 interventionists during the trial with 15 hours of training cov-
ering essentials of HIV management; behavioral science top-
ics, including depression and substance abuse; and the MAPS
manual (available online at http://www.med.upenn.edu/cceb
/maps-form.shtml).
Managed Problem Solving consisted of a 5-step process of
identifying participants’ barriers to adherence, brainstorming
for potential solutions, selecting the best option, monitoring
its implementation and whether the participant considered the
implementation useful, and the participant’s adherence. Un-
successful plans were revised repeating the process. These ac-
tivities were iterated over the first 3 months until an effective
solution was chosen or no further options could be generated.
Baseline screening aided in identifying common potential ad-
herence barriers, using Center for Epidemiologic Studies De-
pression Scale for depressive symptoms,27 the Alcohol Use Dis-
orders Identification Test28 and Addiction Severity Index
questionnaires29 for substance abuse, and a questionnaire re-
garding HIV knowledge, health, and religious beliefs.
The first session began with education concerning the pre-
scribed regimen, medication adherence expectations, common
regimen adverse effects, and medication misperceptions (eg, “if
you drink alcohol, do not take medications that day”). Problem
solving addressed (1) daily routines and daily cues, (2)memory
and cognitive aids for pill taking and prescription refills, and (3)
identifyingandusing social supports as encouragement.Depres-
sion, substanceuse or abuse, toxicitymanagement, and compet-
ing demands were addressed when screening uncovered these
potential barriers. In addition, the interventionist asked open-
ended questions for participants to identify additional barriers.
The MAPS participants met with the interventionist within
2 weeks of initiating therapy for approximately 60 to 90 min-
utes. Three monthly follow-up meetings lasted approximately
20 to 45 minutes. Follow-ups included displaying a calendar
plot of the prior month’s adherence generated by the elec-
tronic monitor. During the first 3 months, weekly telephone
calls reinforced the in-person sessions and allowed for prob-
lem solving of new issues. Monthly telephone calls for the sub-
sequent 9months reminded patients about obtaining refills and
encouraged continuing the adherence strategies.
Prior to working with study patients, mock sessions were
repeated until the interventionist was considered proficient by
the investigators. Subsequently, trained staff assessed fidelity
on 25 randomly selected intervention session audio tapes. Fi-
delity was scored using a 21-item tool developed for the pro-
tocol with scores ranging from 0 to 100; higher values indi-
cated greater fidelity and a score higher than 50was considered
adequate. More details can be found in the MAPS manual.
OUTCOMES
The primary outcome was antiretroviral adherence, measured
using electronicmonitors in all participants (Medication Event
Monitoring System [MEMS], AARDEX), with each bottle op-
ening considered a dose-taking event. Prospective partici-
pants planning to use a pill organizer were required to agree
to maintain 1 medication in the MEMS monitored bottle (ie,
outside of the pill box). For patients receiving multiple anti-
retroviral drugs, an algorithm selected the monitored drug in
the following order of preference: (1) nonnucleoside analog re-
verse transcriptase inhibitor (NNRTI), (2) protease inhibitor
(ritonavir first), (3) integrase inhibitor, (4) entry inhibitor, or
(5) nucleoside reverse transcriptase inhibitors (NRTI).
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We summarized adherence as fraction of prescribed num-
ber of doses taken over each quarter for a year, ranging from 0
to 1. The secondary outcome was undetectable plasma HIV vi-
ral load (UDVL), using a lower limit of 75 copies/mL andmea-
sured quarterly for a year (Versant,HIV-1RNAversion 3.0, Bayer
Corp). These data were collected identically for each group dur-
ing 9 follow-up visits with the study coordinator over the year.
STATISTICAL ANALYSIS
The primary analysis used an “intention to treat” approach. To
bemost conservative,missing valueswere assigned a value of zero
adherence. Fractionof doses takenwas categorized as 0.70or less,
more than 0.70 to 0.80, more than 0.80 to 0.90, more than 0.90
to 0.95, and more than 0.95. Generalized estimating equations
(GEE) with ordinal regression were used to estimate the asso-
ciation between study group and adherence over all 4 quarters
of the year.30 In secondary analyses, we tested for potential con-
foundingbymeasuredvariablesby includingcovariates in theGEE
models and inspecting for changes in the point estimate of the
relation between study group and outcome.
Analyses of viral suppression were identical to those of ad-
herence except using logistic regression.30 In secondary “as
treated” analyses, missing adherence and viral load data were
ignored. In additional analyses, we assessed whether the effect
of the intervention varied over timeby including treatment group
by time interactions in the models.
Finally, we assessed the relation between adherence (inde-
pendent variable) and virologic suppression (dependent vari-
able) again using GEEs with logistic regression and including
missing viral load as detectable.
SAMPLE SIZE
The planned sample size was 200 individuals to achieve greater
than 80% power to detect a less than 10% difference in adher-
ence between MAPS and usual care, ignoring the contribution
of multiple outcome time points per individual. Recruitment
was slower than expected, and the target was decreased to 180




From September 2005 through February 2010, 218 in-
dividuals were referred for participation, with 190 eli-
gible and 180 randomized (95%) (Figure 1). Of those
enrolled, 91 were randomized to MAPS and 89 to usual
care. After the target of 180 was reached, enrollment was
closed and follow-up extended until February 2011.
Participants’ characteristics are displayed in Table 1.
Of the 180 participants, 136 (76%)were receiving 3 drug
regimens with 2 NRTIs and a boosted protease inhibitor
(PI) or an NNRTI (Table 2). The remainder were re-
ceiving various combinations of up to 6 drugs with the
most commonly used NRTI combination being tenofo-
vir and emtricitabine in 88 (49%).
Dropouts occurred for 33 (36%) in the MAPS group
and 23 (26%) in the usual care group (21 = 2.28; P = .13).
TheMAPS participants dropped outmore commonly for
“not wanting to follow the protocol” and moving too far
away to follow-up at the site. Other reasons were simi-
lar between groups. Fidelity to MAPS was high with a
mean (SD) score of 82 (6) points (range, 67-90 points).
Excluded38
Not meeting inclusion criteria
(14 inappropriate regimen, 7
viral load <1000 copies/mL)
21
Declined to participate10




No longer interested in or 
willing to follow protocol
8
Lost to clinical care11
Died1







Not interested in or willing
to follow protocol
2
Lost to clinical care13
Died1






218 Assessed for eligibility
91 Allocated to MAPS 89 Allocated to UC






Figure 1. Participant flowchart. MAPS indicates Managed Problem Solving;
UC, usual care.







Age, median (range), y 43 (20-65) 42 (19-60)
Male sex 52 (57) 56 (63)
Race
Black 80 (88) 73 (82)
White 9 (10) 15 (17)
Other 2 (2) 1 (1)
History of injection drug use 16 (18) 12 (14)
Current drug use 21 (23) 27 (30)
Hazardous alcohol use 14 (15) 18 (21)
Unemployed 73 (85) 69 (78)
Yearly income $5000 24 (28) 33 (36)
Treatment naı¨ve 40 (44) 32 (36)
Once-daily regimen 59 (65) 58 (65)
Pills per regimen, median
(25th-75th quartiles), No.
3 (1-5) 3 (3-5)
Baseline viral load, log10
copies/mL, median
(25th-75th quartiles)
3.24 (2.46-4.32) 3.47 (2.35-4.40)
Baseline CD4 count cells/mm3,
median (25th-75th quartiles)
287 (146-370) 244 (116-379)
Abbreviations: MAPS, Managed Problem Solving; UC, usual care.
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ADHERENCE RESULTS BY STUDY GROUP
The proportion of individuals in each adherence cat-
egory in the MAPS and usual care groups during each
quarter is displayed in Figure 2. In the primary analy-
sis, the odds of being in a higher adherence category at
any follow-up point was 1.78 (95% CI, 1.07-2.96) times
greater for MAPS than usual care. Likewise, in the sec-
ondary analysis using an as-treated approach, the odds
of being in a higher category of adherence at any fol-
low-up point was 2.33 (95%CI, 1.35-4.05) times greater
for MAPS than usual care. In further secondary analyses
controlling for age, race, sex, treatment-naı¨ve status, use
of efavirenz in regimen, baseline viral load, and baseline
CD4 cell count, there was no confounding of the rela-
tion between study group and adherence outcome. There
was no evidence thatMAPS’ adherence effect differed over
time—the study group by time interaction was neither
statistically nor clinically significant (data not shown).
VIROLOGIC RESULTS BY STUDY GROUP
In the intention-to-treat analysis of virologic suppres-
sion, the odds of having an undetectable viral load at any
follow-uppointwas1.48 (95%CI, 0.94-2.31) timesgreater
for MAPS than for usual care. Likewise, in the as-treated
analyses, the odds of having an undetectable viral load at
any follow-up point was 1.98 (95% CI, 1.15-3.41) times
greater for MAPS than usual care. At all time points, vi-
rologic suppression rates forMAPSexceeded thoseofusual
care (Table 3). Again, there was no clear change in the
relation between study group and undetectable viral load
over time. In further formal analyses, there was no evi-
dence thatMAPS’ effect on virologic suppression differed
over time—the study group by time interaction was nei-
ther statisticallynor clinically significant (datanot shown).
EFFECT OF ADHERENCE
ON VIROLOGIC SUPPRESSION
As expected, there was a strong relation between adher-
ence and treatment response. In the analyses wheremiss-
ing viral loads were imputed as “detectable,” for every
25% increase in proportion of doses taken, the odds of
having an undetectable viral load nearly doubled (odds
ratio [OR], 1.99 [95% CI, 1.64-2.41]). In the analyses
wheremissing viral load was left missing, the odds of un-
detectable viral load for every 25% increase in doses taken
was more than double (OR, 2.41 [95% CI, 1.91-3.02]).
OTHER FACTORS ASSOCIATED
WITH ADHERENCE AND VIROLOGIC RESPONSE
Treatment-experienced individuals were 0.48 (95% CI,
0.29-0.81) times as likely to be in a higher adherence cat-
egory and 0.48 (95%CI, 0.30-0.76) times as likely to have
undetectable viral loads than treatment-naı¨ve individu-
als. Higher baseline viral loadwas associatedwith a lower
likelihood of virologic suppression. For every 1 log10
higher baseline viral load, the odds of having an unde-
tectable viral load was 0.80 (95% CI, 0.65-0.99). Nei-
ther of these relationships differed by study group.
COMMENT
This randomized trial of MAPS demonstrated that it is
effective at improving adherence over the first year of a
new antiretroviral regimen in a population with rela-
tively high rates of nonadherence. We found no evi-
dence that MAPS was less effective in individuals with
prior treatment experience despite those individuals being
at higher risk of nonadherence. It did not lose effect over
time. The impact of this increased adherence was borne
out by the higher proportion of individuals with unde-
tectable viral loads. This effect too persisted for the en-
tire treatment period.
Numerous strategies to improve pharmacotherapy ad-
herence have been tested, particularly for antiretroviral
therapy.12 Results have mostly been disappointing, with
only a few strategies showing benefits for both adher-
ence and virologic response.31,32 Directly observed therapy
(DOT) has been themost intensively studied, but, in un-
selected populations, has not been associated with im-
portant33 or sustained benefits.34 However, some evi-
dence suggests that DOT might be useful in select
subpopulations, such as active substance abusers.35 Tech-
nological interventions have hadmixed results with text
messages showing benefit in a developing world set-
ting,32 but not in the developed world.36 Behavioral strat-
egies have also had mixed success. Simple financial in-
centives for adherence have had some effect while
continued, but not consistently, and typically wanewhen
the financial reward is stopped.37 Feedback regarding ad-
herence has been used successfully previously, but in a
population excluding ethnic minorities, substance abus-
ers, and the mentally ill.31 Problem solving has been in-
corporated into larger intervention packages but not stud-
ied on its own.38 Use of multiple modalities to improve
adherence has been suggested for years, but relatively little
evidence to date has been generated. Notably, MAPS in-
corporates both a behavioral strategy and technology—
the adherence feedback is generated via electronic
monitors.
Managed Problem Solving is relatively resource in-
tensive, but such strategies can be presumed to be cost-
effective if they cost less than $1000 per year per par-
ticipant for a 10% increase in adherence.39 Although we







Atazanavir, ritonavir boosted 64 32 32
Efavirenz 48 30 18
Darunavir, ritonavir boosted 31 15 16
Lopinavir, ritonavir boosted 18 6 12
Fosamprenvir, ritonavir boosted 7 4 3
Raltegravir 4 2 2
Nelfinavir 2 1 1
Nevirapine 2 0 2
Tipranavir, ritonavir boosted 1 1 0
Abbreviation: MAPS, Managed Problem Solving.
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did not perform a formal cost-effectiveness analysis, we
estimate that approximately 20 participants were fol-
lowed per year by an interventionist committing 15% ef-
fort at a salary of approximately $50 000 per year. In-
cluding approximately $150 per electronic monitor per
participant, the cost for such an activity is substantially
less than $1000 per year.
There are several potential limitations to this study.
First, although itwas a randomized trial, participants could
not be blinded to study arm. However, since the treat-
ment was crucial to their health, it is unlikely that their
awareness of study arm had an impact on their behavior
outside of the interactionwith the interventionist. In fact,
it is possible that adherence in the control arm was bet-
ter than would be expected in this population since this
condition provided extra visits with the study coordina-
tor, who paid more attention to their medication taking.
Second, participants were recruited from academic spe-
cialty HIV clinics where services for adherence may be
greater than those in general medical clinics. If so, the
effect of MAPSmay be even greater in less resourced set-
tings. Third, it is unclear how the dropouts truly af-
fected the results. Although both the intention-to-treat
and as-treated analyses favoredMAPS, the effectwas stron-
ger in the as-treated analyses. It is possible that imput-
ing virologic failure for allmissing datawas an overly con-
servative assumption. Yet, in all secondary analyses,
changing the assumptions regardingmissing data did not
change the direction of the effect; that is, MAPS was the
favored strategy in all results. Of course, dropouts di-
minish the cost-effectiveness of the intervention; limit-
ing dropouts from care should be a priority for future re-
finements of MAPS. Fourth, we used microelectronic
monitors to generate the feedback over the initial 3
months. The current cost of these monitors may render
them out of reach for most patients and programs. Other
objective techniques have been established for monitor-
ing adherence (eg, pharmacy refill data4,21,40); yet, it is un-
clear how theywould perform if incorporated intoMAPS
instead of microelectronic monitors.
This study also has several particular strengths. The
randomization, and the evident balance between the
groups in most baseline characteristics, minimizes the
likelihood that potential confounders biased the ob-
served effect of MAPS. Second, fidelity to the manual of
procedures always exceeded minimal standards. Third,
the effect was present despite enrolling a populationwith
many life challenges (ie, poverty, unemployment). Fourth,
the effect was apparent in the face of a rigorous and very
conservative analytic approach of considering loss to fol-
low-up nonadherence; this stands in contrast to studies
analyzing only those who remained in care.31 Fifth, the
follow-up period extended for a full year, and there was
no attenuation of the effect. Finally, unlike prior multi-
modal interventions, we have developed an implemen-

































1st 2nd 3rd 4th
Quarter
≤70% >95%>80%-90%>70%-80% >90%-95% ≤70% >95%>80%-90%>70%-80% >90%-95%
Figure 2. Longitudinal distribution of adherence categories. A, Intent-to-treat. B, Categories, as treated. MAPS indicates Managed Problem Solving; UC, usual
care.
Table 3. Virologic Response Rates per Quarter
by Study Group
Proportion With UDVL
Study Group, No. (%)
MAPS Usual Care
Missing = failurea
Q1 53 of 91 (58) 42 of 89 (47)
Q2 53 of 91 (58) 47 of 89 (53)
Q3 52 of 91 (57) 39 of 89 (44)
Q4 54 of 91 (59) 45 of 89 (51)
Missing = missingb
Q1 53 of 68 (78) 42 of 67 (63)
Q2 53 of 62 (86) 47 of 70 (67)
Q3 52 of 69 (75) 39 of 59 (66)
Q4 54 of 72 (75) 45 of 76 (59)
Abbreviations: MAPS, managed problem solving; UDVL, undetectable
plasma human immunodeficiency virus viral load.
aMissing data were analyzed as failure.
bMissing data were ignored in analysis.
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staff in this study. Thus, MAPS has the potential to be
implemented rapidly in settings where health behavior
change expertise is unavailable.
In conclusion, MAPS improves pharmacotherapy ad-
herence, although the benefit was somewhat dimin-
ished by dropouts. Since barriers to adherence and re-
tention in care are similar, MAPS could be expanded to
address retention in care as well; however, that remains
to be evaluated. Since microelectronic monitors are not
widely used in clinical practice, we believeMAPS should
be refined to use other objective measures of adherence
as the feedback tool. With the availability of the inter-
vention manual, MAPS can be used immediately where
the resources exist to implement it. Managed Problem
Solving should also be adapted and tested in other treat-
ment settings where adherence to oral pharmaco-
therapy is critical to health outcomes.
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INVITED COMMENTARY
Lifetime HIV Antiretroviral Therapy
Adherence Intervention
Timing Is Everything
M odern, potent antiretroviral therapy regi-mens can suppress human immunodefi-ciency virus (HIV) replication indefinitely. For
those who have access to these drugs and who are able
to adhere on a daily basis to these drugs, life expectancy
now approaches that of individuals without HIV infec-
tion, particularly if they start therapy early.1,2 Full life-
time viral suppression offers the potentially transforma-
tive public health benefit of reducing transmission leading
to a decline in number of new HIV infections.3
Formanypatients, however, adequate adherence to sus-
tain viral suppression over a lifetime remains amajor chal-
lenge. Antiretroviral adherence declines over time.4-6 Even
people with typically excellent adherence will experience
treatment interruptions owing to inevitable disruptions in
daily routine, relapse of substance use or mental illness,
or simple pill fatigue. Interruptions of several days ormore
put patients at risk for virologic failure.7,8 As such, adher-
ence supportmaybenecessary formany, if notmost, people
at some time in the course of life-long treatment in order
to achieve the full individual and public health impact of
antiretroviral therapy.
Providing adherence support over a lifetime of anti-
retroviral therapy creates 2major conundrums. First,most
adherence interventions are time limited, and benefits do
not typically last much beyond the cessation of the in-
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